Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives $5.33 Average Price Target from Analysts

Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) have been given a consensus recommendation of “Buy” by the six ratings firms that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $5.33.

A number of brokerages recently weighed in on CLSD. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Clearside Biomedical in a research note on Thursday. HC Wainwright restated a “buy” rating and issued a $6.00 price objective on shares of Clearside Biomedical in a report on Thursday. Chardan Capital reiterated a “buy” rating and set a $6.00 target price on shares of Clearside Biomedical in a report on Friday, November 15th. Finally, StockNews.com upgraded Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Thursday, December 12th.

Clearside Biomedical Stock Down 4.9 %

Shares of CLSD stock opened at $0.93 on Friday. Clearside Biomedical has a 12-month low of $0.77 and a 12-month high of $2.12. The firm has a market capitalization of $70.37 million, a price-to-earnings ratio of -2.06 and a beta of 2.10. The firm has a fifty day moving average of $0.96 and a 200-day moving average of $1.06.

Institutional Trading of Clearside Biomedical

Large investors have recently added to or reduced their stakes in the company. Investor s Fiduciary Advisor Network LLC acquired a new stake in Clearside Biomedical in the fourth quarter valued at $32,000. Johnson & Johnson acquired a new stake in Clearside Biomedical in the third quarter valued at $105,000. Northern Trust Corp raised its position in shares of Clearside Biomedical by 24.0% in the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company’s stock valued at $157,000 after purchasing an additional 32,048 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Clearside Biomedical by 8.8% in the third quarter. Geode Capital Management LLC now owns 731,386 shares of the company’s stock valued at $929,000 after purchasing an additional 59,089 shares during the period. Institutional investors and hedge funds own 18.75% of the company’s stock.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.